Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
ASX:MVP'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.44
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Medical Developments International was 0.44. The lowest was 0.00. And the median was 0.04.
ASX:MVP's Debt-to-Equity is ranked better than 88.19% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs ASX:MVP: 0.03
Medical Developments International (ASX:MVP) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Medical Developments International Debt-to-Equity Related Terms
Medical Developments International Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International Debt-to-Equity Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Medical Developments International's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (ASX:MVP) has a Debt-to-Equity of 0.03 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medical Developments International and its competitors. This is 25% below median its historical median of 0.04. According to the industry distribution chart, Medical Developments International ranks #96 out of 813 companies in the Drug Manufacturers industry, placing it in the top 11.8%.
Is Medical Developments International's Debt-to-Equity too high?
Medical Developments International's current Debt-to-Equity of 0.03 is 25% below median its 10-year median of 0.04. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Medical Developments International's value of 0.03 is 88.9% below this industry median. Based on the distribution chart, Medical Developments International ranks #96 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medical Developments International has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #96 out of 813 companies for Debt-to-Equity. This places Medical Developments International in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Medical Developments International's value of 0.03 is 88.9% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.27, Medical Developments International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current Debt-to-Equity of 0.03 is 88.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current Debt-to-Equity is 0.03, which is 25% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.65, compared to a current price of A$0.50 — trading 23.1% below its estimated fair value. The current Debt-to-Equity is 0.03, which is 25% below median its 10-year median of 0.04 and 88.9% below the Drug Manufacturers industry median of 0.27. Medical Developments International's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current Debt-to-Equity is 0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.50 is trading 23.1% below its estimated GF Value™ of A$0.65.
GuruFocus considers Medical Developments International to be Modestly Undervalued.
Key valuation signals for ASX:MVP:
Debt-to-Equity: 0.03 (25% below median its 10-year median of 0.04)
GF Value™: A$0.65 vs. price of A$0.50 (23.1% below fair value)
Industry Position: 88.9% below the Drug Manufacturers median (#96 of 813)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Business Description
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
53GF Score
Get the complete analysis for ASX:MVP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
